Federico Bolognani

Federico Bolognani, MD, PhD has extensive work experience in the medical and scientific field. Federico'smost recent position is as the Vice President and Head of Clinical Development at VectivBio AG since December 2021. Federico also holds a role as a Member of the Scientific and Community Advisory Board of the Simons Foundation SPARK initiative since March 2021. In addition, Dr. Bolognani serves as a Member of the Strategic Advisory Board for CureSHANK since April 2020 and as the Owner of Catran GmbH since November 2020. Federico'sprevious roles include Vice President and Head of Clinical Science at Axial Therapeutics, Inc. from November 2020 to November 2021, and as Vice President and Head of Clinical Science at VectivBio AG from July 2019 to October 2020. Prior to these positions, they held various leadership positions at Therachon, Roche Pharmaceuticals, and Novartis, where they focused on translational medicine, genomics, and neurosurgery research. Dr. Bolognani started their career as a Research Associate in the Department of Neurosurgery at The Methodist Hospital in 2008.

Federico Bolognani, MD, PhD received their MD from the Universidad Nacional de La Plata in 1997. Federico later completed their PhD in gene therapy of pituitary tumors at the same university from 1997 to 2000.